Pliant Therapeutics presented its Phase 1b trial for PLN-101095 targeting ICI-refractory solid tumors at ASCO 2026.
Quiver AI Summary
Pliant Therapeutics, Inc. has announced the presentation of its Phase 1b trial, FORTIFY, focusing on PLN-101095, a first-in-class dual integrin inhibitor, which is currently enrolling patients with immune checkpoint inhibitor-refractory solid tumors. The trial will investigate the safety and potential antitumor efficacy of PLN-101095 in combination with pembrolizumab in patients with advanced or metastatic conditions, specifically targeting those with non-small cell lung cancer, high tumor mutational burden, or clear cell renal cell carcinoma. The presentation is scheduled for May 30, 2026, at the ASCO Annual Meeting in Chicago, where Dr. Timothy A. Yap will discuss the trial's design and objectives. Pliant Therapeutics is committed to developing integrin-based therapies and its lead product is undergoing evaluation in this promising indication expansion trial.
Potential Positives
- Pliant Therapeutics is presenting at the prestigious ASCO Annual Meeting, showcasing its innovative research to a targeted audience of oncology professionals.
- The presentation focuses on PLN-101095, a first-in-class drug, which enhances the company’s positioning in the competitive oncology market.
- The ongoing Phase 1b trial, FORTIFY, indicates active recruitment of patients, demonstrating strong engagement in the clinical study and potential for future results.
Potential Negatives
- Enrollment in the Phase 1b trial may indicate challenges faced in advancing PLN-101095, particularly in the competitive landscape of treatments for ICI-refractory tumors.
- Being in a Phase 1 trial suggests that PLN-101095 is still far from commercialization, which may raise concerns about the company's timeline for potential revenue generation.
- The reliance on pembrolizumab in combination therapy may highlight the uncertainty regarding the efficacy of PLN-101095 as a standalone treatment.
FAQ
What is the FORTIFY trial about?
The FORTIFY trial is a Phase 1b study evaluating PLN-101095 in patients with ICI-refractory solid tumors.
When and where will the ASCO presentation take place?
The ASCO presentation will occur on May 30, 2026, in Hall A, Poster 467b, at the ASCO Annual Meeting in Chicago.
What is PLN-101095?
PLN-101095 is a first-in-class dual integrin inhibitor being developed for treating advanced or metastatic solid tumors.
Who is presenting the poster at ASCO?
Timothy A. Yap, MBBS, Ph.D., from the University of Texas, M.D. Anderson Cancer Center will present the poster.
How are patients being treated in the trial?
Patients will receive PLN-101095 as monotherapy for 14 days before adding pembrolizumab as combination therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095
enrolling patients with ICI-refractory solid tumors
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.
Poster Presentation
| Presenter: | Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center |
| Session: | Developmental Therapeutics – Immunotherapy |
| Date: | Saturday, May 30, 2026, 1:30 – 4:30 p.m. Central Time |
| Location: | Hall A, Poster 467b |
FORTIFY - PLN-101095 Phase 1b Indication Expansion Trial
PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial ( NCT06270706 ) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells.
For additional information on Pliant, visit www.PliantRx.com and follow us on X , LinkedIn and Facebook .
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]
